- Home
- MHI vs TIL Comparison
MHI vs TIL Comparison
Compare MHI & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHI
- TIL
- Stock Information
- Founded
- MHI 2003
- TIL 2018
- Country
- MHI United States
- TIL United States
- Employees
- MHI N/A
- TIL N/A
- Industry
- MHI Investment Managers
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- MHI Finance
- TIL Health Care
- Exchange
- MHI Nasdaq
- TIL Nasdaq
- Market Cap
- MHI 198.1M
- TIL 171.7M
- IPO Year
- MHI N/A
- TIL 2021
- Fundamental
- Price
- MHI $9.29
- TIL $13.68
- Analyst Decision
- MHI
- TIL Buy
- Analyst Count
- MHI 0
- TIL 5
- Target Price
- MHI N/A
- TIL $114.00
- AVG Volume (30 Days)
- MHI 98.8K
- TIL 181.7K
- Earning Date
- MHI 01-01-0001
- TIL 05-20-2025
- Dividend Yield
- MHI 4.09%
- TIL N/A
- EPS Growth
- MHI N/A
- TIL N/A
- EPS
- MHI 0.04
- TIL N/A
- Revenue
- MHI N/A
- TIL N/A
- Revenue This Year
- MHI N/A
- TIL N/A
- Revenue Next Year
- MHI N/A
- TIL N/A
- P/E Ratio
- MHI $219.25
- TIL N/A
- Revenue Growth
- MHI N/A
- TIL N/A
- 52 Week Low
- MHI $6.93
- TIL $9.62
- 52 Week High
- MHI $9.05
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- MHI 61.84
- TIL 45.90
- Support Level
- MHI $9.05
- TIL $11.97
- Resistance Level
- MHI $9.17
- TIL $14.67
- Average True Range (ATR)
- MHI 0.09
- TIL 2.05
- MACD
- MHI 0.05
- TIL 0.04
- Stochastic Oscillator
- MHI 84.13
- TIL 21.18
About MHI Pioneer Municipal High Income Fund Inc.
Pioneer Municipal High Income Trust is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income exempt from regular federal income tax and capital appreciation. The trust invests in various sectors such as health, education, tobacco, facilities, transportation, utilities, airport, water, and other sectors.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.